Genomic Profiling for Prostate and Bladder Cancers
Genomics can reveal the true nature of a patient’s tumor
While clinical information such as stage and pathology are important in evaluating cancer, the unique genomic blueprint of a patient’s tumor is essential in optimizing treatment.
Be confident in treatment decisions
When Decipher is used in formulating a treatment plan, physicians and patients feel more confident that they are making the right decision.
Decipher is standard of care
Decipher testing is covered by Medicare and recommended by clinical practice guidelines for the management of prostate cancer.
Dedicated to improving patient care
Decipher Biosciences is reimagining the use of genomic information to transform and improve cancer patient care.
We are committed to delivering the most accurate tests for determining the true nature of prostate and bladder cancers, enabling each patient to have a treatment plan based on the unique biology of their tumor.
Follow us on
- Decipher Biosciences Announces Publication of a Prospective Clinical Study Demonstrating that the Use of Decipher Prostate RP Guides Post-Operative Management Decisions and Improves Patient Outcomes
- Decipher Biosciences Achieves Major Medicare Milestone for Decipher Prostate Genomic Tests